Biotech Values

[DewDiligence]

>the ITMN-191 1B trial was placebo-controlled<

But it is not blinded, which is the issue apropos to tony’s question about data availability.

>The past comments about low dose have an added clarity now that they are taking about QD potential<

I would take ITMN’s qD-dosing comments with a grain of salt insofar as there is no compelling argument I can see for qD dosing in HCV. ITMN191 will presumably be taken in a cocktail with ribavirin and a polymerase inhibitor and those drugs are dosed BID. (Note that utter dissonance with the HIV market where qD dosing is almost a necessity for commercial success.)